Natural substrates of dipeptidyl peptidase IV

Advances in Experimental Medicine and Biology

Volumn 477, Issue , 2000, Pages 67-87

  De Meester, I ^a   Durinx, C ^a   Bal, G ^a   Proost, P ^a   Struyf, S ^a   Goossens, F ^a   Augustyns, K ^a   Scharpe, S ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CHEMOKINE; CHROMOGRANIN; COLIPASE; DIPEPTIDYL PEPTIDASE IV; ENTEROSTATIN; GASTRIC INHIBITORY POLYPEPTIDE; NEUROPEPTIDE Y; PANCREAS POLYPEPTIDE; PEPTIDE YY; VASOACTIVE INTESTINAL POLYPEPTIDE;

CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD26; CALCITONIN; CALCIUM-BINDING PROTEINS; CALRETICULIN; CHEMOKINES; CHROMOGRANIN A; CHROMOGRANINS; COLIPASES; ENDORPHINS; GLUCAGON; HUMANS; MOLECULAR SEQUENCE DATA; MULTIGENE FAMILY; NEUROPEPTIDE Y; PANCREATIC POLYPEPTIDE; PEPTIDE FRAGMENTS; PEPTIDE YY; PEPTIDES; PROLINE; PROTEIN PRECURSORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RIBONUCLEOPROTEINS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SUBSTANCE P; SUBSTRATE SPECIFICITY; SWINE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0034473089     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (78)

1. The unique properties of dipeptidylpeptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors
2. Human Chemokines: An update
3. The glucagon superfamily: Precursor structure and gene organization
4. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs
5. The inhibition of intestinal dipeptidylaminopeptidase-IV promotes the absorption of enterostafin and des-arginineenterostatin across rat jejunum in vitro
6. Metabolism of enterostatin in rat intestine, brain membranes, and serum: Differential involvement of proline-specific peptidases
7. Development of enzymelinked immunosorbent assay for free human pro-colipase activation peptide (APGPR)
8. Conversion of substance P to C-terminal fragments in human plasma
9. Differential effects of N-terminal modifications on the biological potencies of growth hormone releasing factor analogues with varying chain lengths
10. Structure-activity on the N-terminal region of growth hormone releasing factor
11. Solution structure of eotaxin, a chemokine that selectively recruits eosinophils in allergic inflammation
12. CD26, let it cut or cut it down
13. Glucagon-like peptide-1: A basis for new approaches to the management of diabetes
14. Monoclonal antibodies to human pancreatic procolipase: Production and characterization by competitive binding studies
15. Glucagon-like peptides
16. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV
17. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4 and Y5 receptors in rodents, guinea pig and primate brains
18. Enterostatin - A peptide regulating fat intake
19. 2-terminus
20. Prolyl oligopeptidase: An unusual β-propeller domain regulates proteolysis
21. The purification, characterization and analysis of primary and secondary-structure of prolyl oligopeptidase from human lymphocytes. Evidence that the enzyme belongs to the α/β hydrolase fold family
22. Degradation of β casomorphin-5 by PSE and PPCE. Comparative studies of the β casomorphin-5 cleavage by DPPIV
23. Liver dipeptidyl aminopeptidase IV hydrolyzes substance P
24. Processing of pro-colipase and trypsinogen by pancreatic dipeptidyl peptidase IV
25. Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences
26. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
27. Neuropeptide Y N-terminal deletion fragments: Correlation between solution structure and receptor binding activity at Y1 receptors in rat brain cortex
28. The in vitro intestinal absorption of enterostatin is limited by brush-border membrane peptidases
29. Neuropeptide Y feeding receptors: Are multiple subtypes involved?
30. 11]substance P acts as a biased agonist toward neuropeptide and chemokine receptors
31. Alternative RNA processing events in human calcitonin/calcitonin gene-related peptide gene expression
32. Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes
33. Dipeptidyl peptidase IV: A cell surface peptidase involved in regulating T cell growth
34. Procalcitonin - A new indicator of the systemic response to severe infections
35. Peptide YY: Structure of the precursor and expression in exocrine pancreas
36. Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype
37. Structural requirements for the biological activity of enterostatin
38. Chemokines-chemotactic cytokines that mediate inflammation
39. Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr or Val. Extended DPP-IV substrate specificity?
40. Post-secretory processing of regulatory, peptides: The pancreatic polypeptide family as a model example
41. Dipeptidyl peptidase IV inhibits the polymerization of fibrin monomers
42. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV
43. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is reponsible for their degradation in human serum
44. XVI. International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors
45. Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells
46. The structure and function of CD26 in the T-cell immune response
47. Processing of neuropeptide Y and somatostatin in human cerebrospinal fluid as monitored by radioimmunoassay and mass spectrometry
48. 2-Terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity
49. Stromal cell-derived factor lα by CD26/dipeptidyl peptidase IV
50. Enterostatin (Val-Pro-Asp-Pro-Arg), the activation peptide of procolipase, selectivity reduces fat intake
51. Inhibition of insulin release by enterostatin
52. Regulation of the receptor specificity and function of the chemokine RANTES (Regulated on activatin, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage
53. Hyperenterostatinemia in premenopausal obese women
54. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV
55. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-lα
56. Truncation of macrophage-derived chemokine by CD26/dipeptidylpeptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction
57. CD13 - Not just a marker in leukemia typing
58. A synthetic glucagon-like peptide-1 analog with improved plasma stability
59. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion
60. An islet amyloid peptide is derived from an 89-amino acid precursor by proteolyltic processing
61. Synthesis and in vitro bioactivity of human growth hormone-releasing factor analogs substituted with a single D-amino acid
62. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity
63. Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV
64. Biological activity of GLP-1 analogues with N-terminal modifications
65. CD26/Dipeptidylpeptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of haman eotaxin by affecting its interaction with CC chemokine receptor 3
66. Lipid absorption: Passing through the unstirred layers, brush border membrane, and beyond
67. The role of CD26/DPP IV in chemokine processing
68. Islet amyloid polypeptidedamylin messenger RNA and protein expression in human insulinomas in relation to amyloid formation
69. Structure of the pancreatic iipase-procolipase complex
70. Dipeptidyl peptidase IV/CD26 alternative Tcells: Analysis of an alternative activation pathway
71. Islet amyloid polypeptide (IAPP) and pro-IAPP immunoreactivity in human islets of Langerhans
72. The chromogranins A and B: The first 25 years and future perspectives
73. Isolation of the CXC chemokines ENA-78, GRO alpha and GRO gamma from tumor cells and leukocytes reveals NH2-terminal heterogeneity. Functional comparison of different natural isoforms
74. Proline-dependent structural and biological properties of peptides and proteins
75. Study of the enzymatic degradation of vasostatin I and II and their precursor chromogranin A by dipeptidyl peptidase IV using high-performance liquid chromatography/electrospray mass spectrometry
76. Neuropeptide Y: Implications in vascular remodeling and novel therapeutics
77. Neuropeptide Y: A novel angiogenic factor from the sympathetic nerves and endothelium